These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 968997

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Oral administration of procainamide for ventricular arrhythmia. Plasma concentrations during use of tablets(Pronestyl) and a slow-release preparation (Porcainamide Durettes)].
    Bliddal J.
    Ugeskr Laeger; 1976 Sep 27; 138(40):2425-33. PubMed ID: 968996
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Experiences on a sustained-release procainamide preparation.
    Ruosteenoja R, Torsti P, Sothmann A.
    Curr Ther Res Clin Exp; 1973 Oct 27; 15(10):707-12. PubMed ID: 4201315
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Conversion from intravenous procainamide to oral sustained release tablets in cardiac patients.
    Kalin ML, Babich MF, Klinke WP, Hui WK.
    Can J Cardiol; 1990 Oct 27; 6(1):15-8. PubMed ID: 2310989
    [Abstract] [Full Text] [Related]

  • 8. Antiarrhythmic prophylaxis with procainamide in acute myocardial infarction.
    Koch-Weser J, Klein SW, Foo-Canto LL, Kastor JA, DeSanctis RW.
    N Engl J Med; 1969 Dec 04; 281(23):1253-60. PubMed ID: 4900236
    [No Abstract] [Full Text] [Related]

  • 9. Procainamide in acute myocardial infarction: a study on two different tablet preparations of sustained release type.
    Ihlen H, Ditlefsen L.
    Curr Ther Res Clin Exp; 1975 Nov 04; 18(5):720-6. PubMed ID: 812650
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A new sustained-release tablet formulation of procainamide.
    Fremstad D, Dahl S, Jacobsen S, Lunde PK, Nådland KJ, Marthinsen AA, Waaler T, Landmark KH.
    Eur J Clin Pharmacol; 1973 Dec 04; 6(4):251-5. PubMed ID: 4591152
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical use of sustained-release procainamide in treatment of cardiac arrhythmias.
    Michelson EL, McGeehin FC, Levin BK.
    Angiology; 1988 Jul 04; 39(7 Pt 2):647-54. PubMed ID: 3044199
    [Abstract] [Full Text] [Related]

  • 15. Procainamide acetylation and disposition in dialysis patients.
    Nattel S, Ogilvie RI, Kreeft J, Sitar DS, Graham DN, Rangno RE, Dufresne LR, Barre PE.
    Clin Invest Med; 1979 Jul 04; 2(1):5-11. PubMed ID: 509808
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Immediate-release and sustained-release procainamide: bioavailability at steady state in cardiac patients.
    Vlasses PH, Rocci ML, Porrini KA, Greenspon AJ, Ferguson RK.
    Ann Intern Med; 1983 May 04; 98(5 Pt 1):613-4. PubMed ID: 6189438
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Use of plasma levels in evaluation of procainamide dosage.
    Shaw TR, Kumana CR, Royds RB, Padgham CM, Hamer J.
    Br Heart J; 1974 Mar 04; 36(3):265-70. PubMed ID: 4132893
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.